Glaukos (NYSE:GKOS) Price Target Raised to $251.00

Glaukos (NYSE:GKOS) had its target price boosted by Needham & Company LLC from $201.00 to $251.00 in a report published on Thursday, Marketbeat reports. They currently have a buy rating on the medical instruments supplier’s stock.

GKOS has been the topic of a number of other reports. Citigroup boosted their price objective on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Jefferies Financial Group lifted their target price on shares of Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. BTIG Research lifted their target price on shares of Glaukos from $202.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Finally, Truist Financial boosted their price target on shares of Glaukos from $215.00 to $255.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.71.

Glaukos Trading Down 2.3%

Shares of NYSE GKOS opened at $236.92 on Thursday. The company has a current ratio of 4.57, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Glaukos has a one year low of $80.90 and a one year high of $248.75. The business has a 50-day moving average price of $173.30 and a two-hundred day moving average price of $141.14. The firm has a market capitalization of $14.03 billion, a PE ratio of -80.58 and a beta of 0.69.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. The company had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The firm’s quarterly revenue was up 58.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.16) EPS. As a group, analysts predict that Glaukos will post 0.15 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In related news, CFO Alex Thurman sold 20,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert Kliman sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at approximately $7,107,140. The trade was a 6.26% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 82,500 shares of company stock valued at $14,862,000. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. Provenance Wealth Advisors LLC acquired a new position in Glaukos in the 3rd quarter valued at $44,000. Factory Mutual Insurance Co. bought a new position in Glaukos in the 3rd quarter worth $350,000. Virtue Capital Management LLC acquired a new position in Glaukos during the 3rd quarter worth $303,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in Glaukos during the 3rd quarter worth $1,248,000. Finally, Vise Technologies Inc. acquired a new position in Glaukos during the 3rd quarter worth $668,000. 99.04% of the stock is owned by institutional investors.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported third-quarter revenue of approximately $211 million, up 58% year over year and well above the $168 million analyst consensus. Earnings were $0.47 per share versus expectations for a $0.10–$0.12 loss and a $0.16 loss in the prior-year quarter. Glaukos Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management raised fiscal 2026 revenue guidance to $775 million–$785 million, substantially above the roughly $691.5 million consensus estimate. It also set a preliminary fiscal 2027 sales target of $1 billion, versus Wall Street expectations of about $849 million, reinforcing the growth story. Glaukos sets $1 billion 2027 sales goal
• Positive Sentiment: Analyst sentiment improved following the results. Zacks Research upgraded GKOS from “hold” to “strong buy,” while Needham raised its price target to $251 and JPMorgan lifted its target to $240, maintaining an “overweight” rating.
• Neutral Sentiment: Other firms also raised their targets, including Wells Fargo to $226, BTIG to $234 and Stifel to $225. However, each remains below the recent trading level, suggesting analysts are becoming more constructive while still seeing limited near-term upside at the current valuation.
• Negative Sentiment: The headline profit included factors that may not fully reflect recurring operating earnings. Glaukos continues to report a negative net margin, and commentary noted that underlying profitability is thinner than adjusted figures suggest. With a price-to-earnings ratio based on losses and the stock near its 52-week high, expectations and valuation remain elevated.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.